Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...
GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...
Dr Joshi: Vigilance is the key. The drugs must be taken under strict supervision. Common side effects like nausea, vomitting, ...
Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...
Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
A cardiologist's assertion that Ozempic is a "cardiometabolic medicine" rather than just a weight-loss trend has sparked ...
Danish pharma major Novo Nordisk has announced the launch of Ozempic (injectable semaglutide) in India. The popular ...
The managing director of Novo Nordisk India on Ozempic’s delayed launch in India, leading the fight against diabetes and ...
We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...
Fondazione Telethon ETS' Waskyra has become the first gene therapy in the US for patients with Wiskott-Aldrich syndrome (WAS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback